# Inhibikase Therapeutics, Inc.: overview IKT · Nasdaq · CIK 1750149 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ikt.md) · [Financials](/companies/ikt/financials.md) · [Filings](/companies/ikt/filings.md) · [Insiders](/companies/ikt/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-344707.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-344707). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001193125-25-283169.md) | [0.0 d](/filings/0000950170-25-046096.md) | [0.0](/filings/0001193125-26-219641.md) | [0.0](/filings/0001193125-26-344707.md) | [0.0](/filings/0001193125-25-283169.md) | not reported | [0.0](/filings/0001193125-26-219641.md) | [0.0](/filings/0001193125-26-344707.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.65)](/filings/0001193125-25-283169.md) | not reported | [(0.15)](/filings/0001193125-26-219641.md) | [(0.11)](/filings/0001193125-26-344707.md) | [(0.13)](/filings/0001193125-25-283169.md) | not reported | [(0.10)](/filings/0001193125-26-219641.md) | [(0.11)](/filings/0001193125-26-344707.md) | | Free cash flow | $m | [(4.9) d](/filings/0001193125-25-283169.md) | [(5.3) d](/filings/0001193125-26-126371.md) | [(4.1)](/filings/0001193125-26-219641.md) | [(5.6) d](/filings/0001193125-26-344707.md) | [(10.6) d](/filings/0001193125-25-283169.md) | [(7.5) d](/filings/0001193125-26-126371.md) | [(12.1)](/filings/0001193125-26-219641.md) | [(12.4) d](/filings/0001193125-26-344707.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.1](/filings/0000950170-23-011133.md) | [0.1](/filings/0000950170-24-037160.md) | [0.3](/filings/0000950170-25-046096.md) | [0.0](/filings/0000950170-25-046096.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(476.2%)](/filings/0000950170-23-011133.md) | [(14686.2%)](/filings/0000950170-24-037160.md) | [(7712.0%)](/filings/0000950170-25-046096.md) | not reported | not reported | | Net margin | % | [(476.9%)](/filings/0000950170-23-011133.md) | [(14625.9%)](/filings/0000950170-24-037160.md) | [(7304.7%)](/filings/0000950170-25-046096.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.81)](/filings/0000950170-23-011133.md) | [(4.28)](/filings/0000950170-24-037160.md) | [(3.16)](/filings/0000950170-25-046096.md) | [(1.16)](/filings/0001193125-26-126371.md) | [(0.49)](/filings/0001193125-26-126371.md) | | Free cash flow | $m | [(14.3)](/filings/0000950170-23-011133.md) | [(17.6)](/filings/0000950170-24-037160.md) | [(18.1)](/filings/0000950170-25-046096.md) | [(19.1)](/filings/0001193125-26-126371.md) | [(27.8)](/filings/0001193125-26-126371.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ikt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Sands Capital Alternatives, LLC](/funds/1846444.md) | 2026-06-30 | $26.4m | 13,018,965 | | Unchanged | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $22.1m | 10,875,000 | | Unchanged | | [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $18.4m | 9,051,318 | | Added +993,973 | | [Fairmount Funds Management LLC](/funds/1802528.md) | 2026-06-30 | $17.5m | 8,625,000 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.8m | 7,768,057 | | Added +1,464,624 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $15.0m | 7,387,205 | | Added +780,633 | | [Blackstone Inc.](/funds/1393818.md) | 2026-06-30 | $12.1m | 5,938,276 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $11.9m | 5,850,000 | | Unchanged | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $11.0m | 5,397,488 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.0m | 4,935,354 | | Added +484,689 | ## Recent filings [All 367 filings](/companies/ikt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 20:57 ET | [8-K](/filings/0001193125-26-426811.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-426811 | | 2026-09-08 | 20:41 ET | [8-K](/filings/0001193125-26-385293.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-385293 | | 2026-08-26 | 20:05 ET | [8-K](/filings/0001193125-26-368296.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001193125-26-368296 | | 2026-08-11 | 20:17 ET | [10-Q](/filings/0001193125-26-344707.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344707 | | 2026-08-11 | 20:08 ET | [8-K](/filings/0001193125-26-344623.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344623 | | 2026-07-29 | 20:05 ET | [8-K](/filings/0001193125-26-323651.md) | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-323651 | | 2026-07-23 | 12:32 ET | [8-K](/filings/0001193125-26-313400.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-313400 | | 2026-07-14 | 12:11 ET | [8-K](/filings/0001193125-26-302580.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-302580 | | 2026-06-29 | 10:05 ET | [8-K](/filings/0001193125-26-286747.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-286747 | | 2026-05-12 | 20:39 ET | [10-Q](/filings/0001193125-26-219641.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219641 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-126371.md), filed Mar 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0ba9b93b-8792-40dd-9ef4-78c167676d99) ## About the filer - CIK: 1750149 - Tickers: IKT - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.